EP0485497A4 - Il-2 deletion mutants - Google Patents
Il-2 deletion mutantsInfo
- Publication number
- EP0485497A4 EP0485497A4 EP19900912554 EP90912554A EP0485497A4 EP 0485497 A4 EP0485497 A4 EP 0485497A4 EP 19900912554 EP19900912554 EP 19900912554 EP 90912554 A EP90912554 A EP 90912554A EP 0485497 A4 EP0485497 A4 EP 0485497A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- deletion mutants
- mutants
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US388557 | 1982-06-15 | ||
| US38855789A | 1989-08-02 | 1989-08-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0485497A1 EP0485497A1 (en) | 1992-05-20 |
| EP0485497A4 true EP0485497A4 (en) | 1992-07-08 |
Family
ID=23534610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19900912554 Withdrawn EP0485497A4 (en) | 1989-08-02 | 1990-07-30 | Il-2 deletion mutants |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0485497A4 (en) |
| JP (1) | JPH04507250A (en) |
| AU (1) | AU6179990A (en) |
| CA (1) | CA2064696A1 (en) |
| NZ (1) | NZ234674A (en) |
| WO (1) | WO1991002000A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0584251A4 (en) * | 1991-05-17 | 1995-08-02 | Seragen Inc | MOLECULES TARGETED TO A CYTOKINE RECEPTOR BY THE TREATMENT OF NEOPLASTIC CELL GROWTH. |
| US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| DE60332358D1 (en) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN105722860A (en) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | Interleukin-2 fusion proteins and uses thereof |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111201035A (en) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Uses and methods of IL-2 superagonists, agonists and fusions thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| EP3854805A4 (en) * | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NEW INTERLEUKIN 2 AND ITS USE |
| BR112021023345A2 (en) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Targeted immunotolerance in madcam |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| JP2023518434A (en) * | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | Interleukin-2 mutants and uses thereof |
| AU2021237518B2 (en) * | 2020-03-19 | 2024-08-15 | Fortvita Biologics (Singapore) Pte.Ltd. | Interleukin-2 mutant and use thereof |
| EP4406965A4 (en) * | 2021-09-22 | 2025-12-17 | Fortvita Biologics Singapore Pte Ltd | MUTANT INTERLEUKIN-2 AND ITS FUSING PROTEIN |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985000817A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
-
1990
- 1990-07-27 NZ NZ234674A patent/NZ234674A/en unknown
- 1990-07-30 WO PCT/US1990/004258 patent/WO1991002000A1/en not_active Ceased
- 1990-07-30 EP EP19900912554 patent/EP0485497A4/en not_active Withdrawn
- 1990-07-30 AU AU61799/90A patent/AU6179990A/en not_active Abandoned
- 1990-07-30 CA CA002064696A patent/CA2064696A1/en not_active Abandoned
- 1990-07-30 JP JP2511867A patent/JPH04507250A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| PROTEIN ENGINEERING. vol. 1, no. 6, 1987, EYNSHAM, OXFORD, ENGLAND GB pages 493 - 498; D. P. WILLIAMS ET AL: 'Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein' * |
| See also references of WO9102000A1 * |
| TRANSPLANTATION vol. 47, no. 2, February 1989, BALTIMORE pages 318 - 322; O. PANKEWYCZ ET AL: 'Interleukin-2-diphteria toxin fusion protein prolongs murine islet cell engraftment' * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6179990A (en) | 1991-03-11 |
| EP0485497A1 (en) | 1992-05-20 |
| CA2064696A1 (en) | 1991-02-03 |
| JPH04507250A (en) | 1992-12-17 |
| NZ234674A (en) | 1992-02-25 |
| WO1991002000A1 (en) | 1991-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0485497A4 (en) | Il-2 deletion mutants | |
| AR244339A1 (en) | Subtilisin mutants | |
| GB8806923D0 (en) | Lubricants | |
| ZA895408B (en) | Lubricant composition | |
| EP0346283A3 (en) | Lubricant composition | |
| GB8924057D0 (en) | Lubricants | |
| EP0487099A3 (en) | Bacteriorhodopsine - double mutants | |
| AU106904S (en) | High chair | |
| EP0414357A3 (en) | Keyboard interface | |
| EP0291055A3 (en) | Stable creatinamidinohydrolase mutants | |
| ZA895225B (en) | Anti-oxidants | |
| EP0349131A3 (en) | Lubricant composition | |
| GB2237737B (en) | Occasional furniture | |
| AU5231690A (en) | Fluoroalkyl thiophosphates | |
| EP0471647A3 (en) | Restriction-deficient mutants | |
| GB2214797B (en) | Desk | |
| GB8914201D0 (en) | Potentiometer | |
| IE892327L (en) | Mutants of desulphatohirudin | |
| IE892326L (en) | Mutants of desulphatohirudin | |
| AU108051S (en) | Desk | |
| AU107153S (en) | Desk | |
| AU108174S (en) | Desk | |
| GR2000742Y (en) | Original desks | |
| GB2216359B (en) | Synchronisation | |
| GB8902551D0 (en) | Lubricants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19920207 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19920521 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: AKIYOSHI, DONNA, E. Inventor name: GENBAUFFE, FRANCIS, S., JR. |
|
| 17Q | First examination report despatched |
Effective date: 19940308 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19960703 |